Biogen

Selected news for the company - Biogen, collected since 10/2017. This company shares news with Food and Drug Administration, Biotech, Novartis, Pfizer, Medicare and hundreds of others.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source Relevant Snippet
1/13/2022 Medicare Proposes to Restrict Coverage of Controversial and Costly Alzheimer's Drug Yahoo News Medicare officials on Tuesday proposed limiting coverage of a controversial and expensive new Alzheimer’s drug to patients in approved clinical trials. The proposal could sharply limit the number of patients who use Biogen ’s Aduhelm, a monoclonal antibody treatment for Alzheimer’s, which has faced questions about both its cost and its effectiveness. The decision also applies to similar drugs in development.The preliminary proposal by the Centers for ...
1/13/2022 Insurers applaud CMS' proposal for Medicare to only cover Aduhelm for seniors in clinical trials | FierceHealthcare FierceHealthcare ... the drug’s safety and effectiveness,” said Adam Myers, M.D., senior vice president and chief clinical transformation officer for the association.The Food and Drug Administration granted accelerated approval in June 2021 to Biogen ’s Aduhelm to target beta amyloid plaques in the brain, despite objections from agency advisers over its effectiveness. But there has been a major blowback from insurers over whether to cover the drug, especially after ...
1/12/2022 Medicare proposes coverage limits for Alzheimer's drug Aduhelm – KIRO 7 News Seattle kiro7.com WASHINGTON — Medicare said Tuesday that it will cover a controversial - and pricey - new Alzheimer’s drug only for patients enrolled in qualifying clinical trials. Read more trending newsThe drug, Biogen ’s Aduhelm, received FDA approval in June and was touted as the first new drug to treat the leading cause of dementia in nearly 20 years. Independent advisers argued at that time, however, that little evidence exists to ...
1/12/2022 Truist Securities Cuts Biogen (NASDAQ:BIIB) Price Target to $343.00 - Ticker Report Ticker Report ... Äô target price suggests a potential upside of 42.02% from the company‚Äôs previous close.Several other research analysts have also issued reports on the stock. Barclays cut their target price on shares of Biogen from $395.00 to $290.00 and set an ‚Äúequal weight‚Äù rating on the stock in a research note on Friday, October 8th. SVB Leerink dropped their price objective on shares of Biogen from $450.00 to ...
1/12/2022 Biogen (NASDAQ:BIIB) PT Lowered to $328.00 at Needham & Company LLC - The Cerbat Gem thecerbatgem.com ... The brokerage currently has a buy rating on the biotechnology company’s stock.Other equities research analysts have also recently issued research reports about the stock. Cowen increased their price target on shares of Biogen from $375.00 to $450.00 and gave the company an outperform rating in a research report on Thursday, October 21st. Wells Fargo & Company raised their target price on shares of Biogen from $250.00 to $284.00 in ...
1/12/2022 Ticker: ARPA infusion boosts fuel aid; Medicare limits coverage of Alzheimer's drug Boston Herald ... Tuesday it will limit coverage of a $28,000-a-year Alzheimer’s drug whose benefits have been widely questioned.The initial determination from the Centers for Medicare and Medicaid Services means that patients taking Biogen ’s Aduhelm medication will have to be part of research efforts to assess the drug’s effectiveness in slowing the progression of dementia. Medicare’s national coverage determination would become final this spring, following a ...
1/12/2022 Medicare limits coverage of $28,000-a-year Alzheimer's drug – Boston Herald Boston Herald ... the fair value of new medicines that offer tantalizing possibilities but come with prohibitive prices.The initial determination from the Centers for Medicare and Medicaid Services means that for Medicare to pay, patients taking Biogen ’s Aduhelm medication will have to be part of clinical trials to assess the drug’s effectiveness in slowing the progression of early-stage dementia as well as its safety.Medicare’s national coverage determination ...
1/12/2022 Biogen Stock Slumps As Medicare Limits Alzheimer's Drug Coverage - TheStreet TheStreet Biogen ( BIIB ) - Get Biogen Inc. Report shares slumped lower Wednesday after the U.S. government's Medicare program said it will limit access to the drugmaker's newly-approved Alzheimer's treatment. The U.S. Centers for Medicare and Medicaid Services said it will only cover treatment with Aduhelm, Biogen 's Alzheimer's treatment, if patients are enrolled in a clinical trial. The decision, which could be ...
1/12/2022 JPM22, Day 3: BeiGene, Ionis promise 'tidal wave' of new drugs; Roche launches smart, point-of-care glucose monitor | FierceBiotech FierceBiotech ... wrapped here . We'll finish off the event with another compilation of our stories on Thursday's Day 4.UPDATED: Wednesday 10:33 a.m. ETFlush with $2 billion in cash and recent partnerships with AstraZeneca and Biogen , Ionis Pharmaceuticals expects to have a “tidal wave of drugs” reaching the market by 2030, said Brett Monia , Ph.D., CEO and cofounder, at the annual J.P. Morgan Healthcare Conference. The pharma will take eplontersen ...
1/12/2022 Medicare considers covering cost of Aduhelm for clinical trial participants only McKnight's Long Term Care News ... and is delivered using repeat infusions. The FDA approved it in 2021 under a cloud of controversy over its efficacy, soaring cost and accessibility. Aduhelm costs $28,000 per patient per year, according to maker Biogen , which recently cut the cost from $56,000.CMS’s new coverage proposal also applies to other FDA-approved drugs in its class that — like Aduhelm — specifically target amyloid brain plaques for the treatment ...
1/12/2022 CMS proposes limited coverage of Biogen Alzheimer's drug, only in clinical trials - MedCity News MedCity News ... June granted the drug accelerated approval . Such decisions are based on a surrogate endpoint, an indication that a drug might be working. Benefit of the drug must be demonstrated in post-marketing studies, which Biogen plans to begin later this year .The proposed CMS decision notes that to date, no clinical trial of an amyloid-targeting antibody drug has shown clinically meaningful improvement in cognition and function in Alzheimer’s ...
1/12/2022 For Biogen's Aduhelm, narrow coverage from CMS 'could effectively spell the end': analyst FiercePharma ... Aduhelm, Jefferies analyst Michael Yee said in a separate note. It would limit access to no more than several thousands of patients, SVB Leerink analyst Marc Goodman pointed out in his note. By contrast, Biogen had estimated roughly 50,000 patients could start treatment this year if a Medicare reimbursement policy were in place.Biogen has been advocating for coverage with restrictions that mirror the enrollment criteria for Aduhelm’s phase ...
1/12/2022 JPM 2022: Eli Lilly gears up for Alzheimer's-diabetes juggling act as 2 key FDA decisions loom FiercePharma ... meds in question are the dual GIP/GLP-1 agonist tirzepatide, a Type 2 diabetes candidate with ambitions to break into obesity, and donanemab, the anti-amyloid antibody that may soon run up against Biogen ’s Alzheimer’s disease drug Aduhelm. Juggling multiple launches isn’t easy, but much of the “trick” to commercial execution comes down to “understanding when you can do things in a common way †...
1/12/2022 Biogen extends losses as Wall Street weighs in on Medicare decision on Aduhelm Seeking Alpha Biogen extends losses as Wall Street weighs in on Medicare decision on Aduhelm- Biogen (NASDAQ: [BIIB] ) has extended post-market losses to trade ~9.9% lower in early trading after the U.S. government announced its decision on Tuesday to severely restrict the access to Aduhelm and other similar Alzheimer’s drugs only for [those enrolled in clinical trials.]- The proposed decision by the Centers for Medicare & Medicaid Services (CMS) is preliminary ...
1/12/2022 Biogen plans flood of public comments in response to Medicare decision - Endpoints Seeking Alpha Biogen plans flood of public comments in response to Medicare decision - Endpoints- Biogen plans to inundate the Centers for Medicare & Medicaid Services ("CMS") with public comments in response to the agency's decision yesterday to [drastically limit coverage of the Alzheimer's treatment Aduhelm (aducanumab)] .- Those comments will come over the next 30 days, according to [Endpoints News] , which obtained an internal company email with the details.- "If this draft becomes final ...
1/12/2022 Biotech Stock Roundup: BIIB's AD Drug Update, AMGN's Drug Approval & Other Updates | Nasdaq Nasdaq Quite a few regular pipeline and regulatory updates grabbed focus in the biotech sector this week. Importantly, updates on COVID-19 vaccines and treatments continue to be in the spotlight amid the rapidly spreading Omicron variant.Recap of the Week’s Most Important Stories : Biogen Down on Medicare Update : Shares of Biogen BIIB were down after its controversial Alzheimer’s disease (AD) drug Aduhelm faced another setback. The Centers for ...
1/12/2022 Why Biogen Stock Is Sinking Today | Nasdaq Nasdaq What happened Shares of Biogen (NASDAQ: BIIB) were sinking 9.5% as of 10:48 a.m. ET on Wednesday. The decline came after the Centers for Medicare and Medicaid Services (CMS) on Tuesday released its proposed National Coverage Determination (NCD) for Biogen's Alzheimer's disease drug Aduhelm. The proposed NCD would only cover Aduhelm for Medicare beneficiaries enrolled in clinical trials.So what Biogen had hoped that CMS would decide to provide full ...
1/12/2022 Biogen (BIIB) Down on Medicare Draft Ruling for Alzheimer's Drugs | Nasdaq Nasdaq ... draft ruling.Biogen, in response to the proposed NCD decision, said that it will deprive nearly all Medicare beneficiaries from accessing Aduhelm and the draft ruling needs to be changed.So far this year, Biogen ’s shares have declined 9.4% compared with the industry ’s decrease of 30.7% in the same time frame.Image Source: Zacks Investment ResearchIn fact, the stock has declined almost 40% since the FDA approved ...
1/12/2022 Biogen hits Medicare wall | Nasdaq Nasdaq ... own.)NEW YORK (Reuters Breakingviews) - Drug investors are worried the preliminary U.S. government decision to restrict https://www.cms.gov/newsroom/press-releases/cms-proposes-medicare-coverage-policy-monoclonal-antibodies-directed-against-amyloid-treatment payment for Biogen ’s new Alzheimer’s treatment is a Trojan horse that presages more sweeping limits on medical spending. But the decision is unlikely to be a precedent given how much is exceptional in this story.The ...
1/12/2022 Why Biogen's Medicare mess is bad for the pharmaceutical industry - STAT STAT Matt's Take Why Biogen’s Medicare mess is bad for the pharmaceutical industry By Matthew Herper Jan. 12, 2022ReprintsRuby Wallau for STATM edicare’s proposal that it will cover Alzheimer’s drugs such as Biogen’s embattled Aduhelm only in clinical trials could have a simple but difficult result for the pharmaceutical industry: chaos.The draft decision released yesterday is a response to the June choice by ...